CybeRelease: (OTC BB: AMZB) Negotiates Sale of Its AIDS Drug

(CybeRelease, December 19, 2006) - Lake Harmony, PA - Amazon Biotech, Inc. (OTC BB:AMZB.OB - News) (Frankfurt:B2D.F - News), announced today that it is in negotiations with a European company to obtain approvals for sale of its AIDS drug in Nigeria and Kenya.

Dr. Mechael Kanovsky, President of Amazon Biotech Inc., stated: “Obtaining these licenses will be an important step for the company. We believe that our drug will have a positive impact on the AIDS epidemic in Africa.”

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

For more information, go to http://biz.yahoo.com/iw/061219/0196799.html .

For a Free Newsletter, go to http://www.OTCReporter.com.

CybeRelease Gainers are Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), Immunomedics, Inc. (Nasdaq: IMMU), TSR, Inc. (Nasdaq: TSRI), Silver Standard Resources, Inc. (Nasdaq: SSRI), Ventiv Health, Inc. (Nasdaq: VTIV), Royal Gold, Inc. (Nasdaq: RGLD),Captaris Inc. (Nasdaq: CAPA) and Arotech Corporation (Nasdaq: ARTX),.

CybeRelease Decliners are Ness Technologies, Inc. (Nasdaq: NSTC), Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), Pointer Telocation Ltd. (Nasdaq: PNTR), ClickSoftware Technologies Ltd. (Nasdaq: CKSW), DayStar Technologies, Inc. (Nasdaq: DSTI), Irvine Sensors Corporation (Nasdaq: IRSN), Bio-Reference Laboratories, Inc. (Nasdaq: BRLI) and Oscient Pharmaceuticals Corporation (Nasdaq: OSCI).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send No Faxes or Emails.

Contact Information

C. P. Barry

Media Contact

CybeRelease.com

Contact via E-mail